news 
This Next Generation IVF Startup Facilitated The Birth Of A Baby For The First Time
Dina Radenkovic and her team at Gameto have achieved a groundbreaking milestone. On December 7, the first baby conceived using their innovative in-vitro fertilization (IVF) technology was born, marking a significant shift in the IVF industry.
As the co-founder of Gameto, Radenkovic has dedicated years to developing a new approach to IVF that reduces the invasiveness and discomfort associated with traditional methods. The breakthrough came after her team at Harvard’s Wyss Institute discovered a way to mature eggs outside the mother’s body.
The revolutionary technology, called Fertilio, eliminates the need for multiple injections of hormones, drastically reducing the duration and number of injections by nearly 80 percent. This not only minimizes discomfort but also reduces costs and increases accessibility to IVF treatment.
Dr. Brian Levine, a fertility expert from CCRM in New York, commends Gameto’s innovative approach. “This product could help reduce the intrinsic cost of IVF because someone would only take medication for a couple of days,” he explains. “If this product could help stimulate someone for just three or four days, that could be all the difference between providing access to care and no access to care.”
Gameto’s new method has shown remarkable results in clinical trials, with Fertilio now approved by regulators in six countries. The technology is currently available commercially in Australia, Mexico, Argentina, and Peru, with plans to expand into Japan and Paraguay.
In the United States, Gameto is preparing for Phase 3 clinical trials, which are expected to begin in 2025. This milestone marks a significant step forward for the company’s goal of eventually obtaining FDA approval.
As the IVF industry prepares for disruption, Radenkovic and her team remain committed to convincing the market that their technology is ready for widespread adoption. “We’ve achieved so much in the past three years, and we’ve been laser-focused on execution,” she emphasizes. “I do believe that great science can be built in great companies. That’s why I went into healthcare, because you can have a positive impact as well as build a great business.”
This achievement not only marks a groundbreaking moment for Gameto but also highlights the company’s dedication to creating more accessible and effective IVF treatment options for individuals worldwide.
Source: www.forbes.com
